Covid-19 task force member NK Arora has admitted that the supply of Bharat Biotech’s Covaxin slowed down because the first few batches of ...
Covid-19 task force member NK Arora has admitted that the supply of Bharat Biotech’s Covaxin slowed down because the first few batches of the vaccine produced at the company’s new facility did not meet quality expectations, reported NDTV on Monday.
Arora, the chairperson of the Working Group of the National Technical Advisory Group on Immunisation, clarified that the batches that did not meet the quality standards were not released to the public.
In an interview with NDTV, Arora added that the problem has been resolved now. “But the third and fourth batches have now come up which have moved forward,” he said. “We hope in the next four or six weeks the vaccine production will really ramp up from Bharat Biotech.”
Arora said that the new facility in Bengaluru was one of the largest vaccine manufacturing plants globally and the production of the vaccines will be ramped up. “In addition, three public sector undertaking are also working together to augment the total output,” he told the news channel. “Ultimately we are expecting 10-12 crore doses from Bharat Biotech.”
To meet the Centre’s target of vaccinating all adults by December-end, India needs 30 crore vaccines doses a month to inoculate about a crore citizens a day. When asked if Bharat Biotech can...
